Skip to main content
. 2012 Mar 21;22(5):709–722. doi: 10.1111/j.1750-3639.2012.00577.x

Figure 6.

Figure 6

Klk6‐neutralizing antibodies attenuate brain pathology at early but not chronic stages of TMEV‐induced demyelinating disease. Analysis of total brain pathology based on the average of all pathology assessed in the cerebellum, brain stem, striatum, cortex, hippocampus, corpus callosum and meninges at 40 (A, C) and 180 days (B) post‐TMEV infection. (A) Histogram depicting total brain pathology scores shows significantly less pathology in mice with high levels of circulating Klk6‐neutralizing antibodies prior to TMEV infection when assessed at the 40‐day time point (ANOVA, P = 0.006; *SNK, P < 0.05). At 180 days post‐TMEV‐infection (B), there were no statistically significant differences between the groups examined. (C) shows the distribution of pathology severity in each region of the brain examined at 40 days after TMEV infection.